Compare PERI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PERI | CTNM |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 507.0M |
| IPO Year | 2005 | 2024 |
| Metric | PERI | CTNM |
|---|---|---|
| Price | $9.00 | $12.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.75 | ★ $19.80 |
| AVG Volume (30 Days) | ★ 412.6K | 242.0K |
| Earning Date | 02-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.00 | $3.35 |
| 52 Week High | $11.44 | $16.33 |
| Indicator | PERI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 37.12 |
| Support Level | $8.82 | $10.39 |
| Resistance Level | $9.15 | $13.18 |
| Average True Range (ATR) | 0.26 | 1.19 |
| MACD | 0.04 | -0.32 |
| Stochastic Oscillator | 75.74 | 7.64 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.